Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Phase 2/3 Study of Setrusumab in Osteogenesis Imperfecta
2021-006597-23Phase 2Active
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing Setrusumab with Placebo (2 arms). Primary endpoint: Percent change in serum P1NP from baseline at Month 1. Started May 2022; status: active.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2021-006597-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006597-23.